Kineta Inc. Adds to Its Pipeline of Venom-Derived Drug Candidates, In-licenses Conotoxin Program for Non-Narcotic Pain Relief

Published: Jan 25, 2013

SEATTLE--(BUSINESS WIRE)--Kineta is pleased to announce it has secured exclusive, worldwide development rights from the University of Utah Research Foundation to a portfolio of drug candidates based on the Conotoxin Rg1a for the non-narcotic treatment of chronic pain. Derived from the Rg1a peptide found in the venom of cone snails, these molecules were discovered in the pioneering laboratory of Baldomero Olivera, Ph.D. and are featured in an article in the February issue of National Geographic magazine.

Back to news